+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Effects of gastric medicines on gastroduodenal injury in patients with stable angina during antiplatelet therapy



Effects of gastric medicines on gastroduodenal injury in patients with stable angina during antiplatelet therapy



Journal of Cardiology 54(1): 71-75



The aim of this study was to examine the effects of gastric medicines on gastroduodenal injury during antiplatelet therapy after coronary intervention. A total of 501 patients were enrolled and as dual antiplatelet therapy, aspirin and thienopyridine were administered. Patients were divided into four groups: histamine H2-receptor antagonists (H2RA); proton pump inhibitors (PPI); other gastromucosal protective agents (GMP); or nothing (None), and follow-up lasted 8-20 months. H2RA were prescribed in 212 cases (42%), PPI in 150 (30%), GMP in 56 (11%), and None in 83 (17%). Significant findings by endoscopy were recognized in 18 cases and upper gastrointestinal bleeding requiring hospitalization occurred in 7 patients (1.4%; H2RA in 4, GMP in 2, and None in 1). There were no gastrointestinal injuries in the PPI group. To minimize the effect of selection bias on gastroduodenal lesions, the propensity score analysis for clinical characteristics was used. The results of propensity score matching showed that administration of PPI reduced the incidence of gastrointestinal lesions compared with that of the non-PPI group. Administration of PPI reduced the incidence of gastrointestinal lesions compared with that of the non-PPI group.

(PDF emailed within 0-6 h: $19.90)

Accession: 052868258

Download citation: RISBibTeXText

PMID: 19632523

DOI: 10.1016/j.jjcc.2009.04.002


Related references

Effects of pantoprazole on dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention. Pharmacological Reports 64(2): 360-368, 2012

Gastroduodenal mucosal injury in patients on antiplatelet therapy. Thrombosis Research 120(4): 465-469, 2007

Selection of antiplatelet therapy for patients with stable angina. Kardiologiia: 36-41, 2018

Antiplatelet Therapy During PCI for Patients with Stable Angina and Atrial Fibrillation. Current Cardiology Reports 17(8): 64-64, 2016

Antiplatelet effects of nitroglycerin in healthy subjects and in patients with stable angina pectoris. Journal of Cardiovascular Pharmacology 21(3): 384-389, 1993

N-3 polyunsaturated fatty acids do not influence the efficacy of dual antiplatelet therapy in stable angina pectoris patients after percutaneous coronary intervention. Cardiology Journal 20(5): 478-485, 2014

Obesity and antiplatelet effects of acetylsalicylic acid and clopidogrel in patients with stable angina pectoris after percutaneous coronary intervention. Polskie Archiwum Medycyny Wewnetrznej 125(9): 620-630, 2015

AS-260: Triple versus Dual Antiplatelet Therapy in Chronic Stable Angina Patients Undergoing Elective Percutaneous Coronary Intervention with Drug-Eluting Stents. American Journal of Cardiology 105(9-Supp-S): 110-0, 2010

Effects of clinical indices and anti-angina therapy on the quality of life in patients with stable angina pectoris. Klinicheskaia Meditsina 79(7): 28-31, 2001

Comparison of the pharmacodynamic effects of ranolazine versus amlodipine on platelet reactivity in stable patients with coronary artery disease treated with dual antiplatelet therapy : The ROMAN (RanOlazine vs. aMlodipine on platelet reactivity in stable patients with CAD treated with dual ANtiplatelet therapy) study. Journal of Thrombosis and Thrombolysis 40(3): 331-339, 2016

AS-256: Triple versus Dual Antiplatelet Therapy in Chronic Stable Angina Patients with Diabetes Undergoing Elective Percutaneous Coronary Intervention with Drug-Eluting Stents. American Journal of Cardiology 105(9-Supp-S): 108-109, 2010

Effects of ranolazine on exercise tolerance and angina frequency in patients with severe chronic angina receiving maximally-tolerated background therapy: analysis from the Combination Assessment of Ranolazine In Stable Angina (CARISA) randomized trial. European Journal of Preventive Cardiology 19(5): 952-959, 2013

The impact of guideline compliant medical therapy on clinical outcome in patients with stable angina: findings from the Euro Heart Survey of stable angina. European Heart Journal 27(11): 1298-1304, 2006

Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome. Platelets 26(6): 521-529, 2016

Effects of long-term oral dipyridamole treatment on coronary microcirculatory function in patients with chronic stable angina: A substudy of the persantine in stable angina (PISA) study. Journal of Cardiovascular Pharmacology 48(3): 110-116, 2006